Y. Ye, D. Wang, C. Su, T. Rong, A. Guo
Published: December 23, 2009
Genet. Mol. Res. 8 (4) : 1509-1518
DOI: https://doi.org/10.4238/vol8-4gmr627

Cite this Article:
Y. Ye, D. Wang, C. Su, T. Rong, A. Guo (2009). Combined detection of p53, p16, Rb, and EGFR mutations in lung cancer by suspension microarray. Genet. Mol. Res. 8(4): 1509-1518. https://doi.org/10.4238/vol8-4gmr627

About the Authors
Y. Ye, D. Wang, C. Su, T. Rong, A. Guo

Corresponding author
D. Wang
E-mail: wangdong_nj001@hotmail.com

ABSTRACT

Mutations of some contributing factors (p53, p16, Rb, and EGFR) are believed to affect diagnosis and drug resistance of lung cancer. We evaluated the efficacy of a multimarker panel for molecular diagnosis of lung cancer, using a high-throughput suspension microarray. One hundred and twenty-five lung cancer specimens and 30 tumor-free lung tissue samples were assayed by multiplex polymerase chain reaction with specific probes designed to detect hot-spot mutations in p53, p16, Rb, and EGFR. The mutation rates of p53, p16, Rb, or EGFR in the lung cancer specimens were 36.8, 15.2, 11.2, and 18.4%, respectively. Inclusion of four markers elevated sensitivity to 68.0%. The specificity and accuracy of four-marker detection were 90.0 and 72.3%, and the mutation rates of this panel in stage I, stage II and stage III disease were 62.2, 65.9 and 75.0%, respectively. Mutation at p16 occurred more frequently in non-small cell lung cancer (19.3%) than in small cell lung cancer (5.4%); while the mutation rate of Rb was 32.4% in small cell lung cancer versus 2.3% in non-small cell lung cancer. We conclude that simultaneous detection of p53, Rb, p16, and EGFR in a suspension microarray facilitates rapid diagnosis of lung cancer.

Key words: Lung cancer, Diagnosis, p53, p16, Rb, EGFR.